Ticker LaunchIPO · RVMD
Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) priced its initial public offering on Feb 13, 2020 at $17.00 per share, within its $16.00–$17.00 range, raising $238M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $967.3M. J.P. Morgan was lead-left underwriter, joined by TD Cowen, Leerink Partners and Guggenheim. Latham & Watkins advised the company and Davis Polk advised the underwriters.
- Status
- IPO
- Ticker
- RVMD
- Exchange
- Nasdaq Global Select
- Priced
- Feb 13, 2020
- IPO price
- $17.00
- Price range
- $16.00–$17.00
- Raised
- $238M
- Market cap at IPO price
- $967.3M
- First filed
- Jan 17, 2020
- Underwriters
- J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim
- Company counsel
- Latham & Watkins
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 17, 2020
- Latest amendment Feb 11, 2020
- Final prospectus (424B4) Feb 13, 2020
- All filings on EDGAR CIK 1628171
Other Biotech & pharma IPOs in 2020
- Beam Therapeutics Inc.BEAM · Feb 7, 2020 · $180M
- PPD, Inc.PPD · Feb 6, 2020 · $1.62B
- Schrodinger, Inc.SDGR · Feb 6, 2020 · $202M
- Arcutis Biotherapeutics, Inc.ARQT · Jan 31, 2020 · $159.4M
- Annovis Bio, Inc.ANVS · Jan 30, 2020 · $12M
- Black Diamond Therapeutics, Inc.BDTX · Jan 30, 2020 · $201.1M